» Articles » PMID: 32046748

JCPyV NCCR Analysis in PML Patients with Different Risk Factors: Exploring Common Rearrangements As Essential Changes for Neuropathogenesis

Abstract

Background: During severe immunosuppression or treatment with specific biological drugs, human polyomavirus JC (JCPyV) may establish a lytic infection in oligodendrocytes, leading to progressive multifocal leukoencephalopathy (PML). Beyond AIDS, which represents the most common predisposing condition, several biological drugs have been associated to the development of PML, such as natalizumab, fingolimod and dimethyl fumarate, which have been showed to increase the risk of PML in the multiple sclerosis (MS) population. JCPyV non-coding control region (NCCR) can be found in two different forms: a virulent neurotropic pathogenic form and a latent non-pathogenic form. The neurotropic forms contain a rearranged NCCR and are typically found in the cerebrospinal fluid, brain or blood of PML patients.

Case Presentation: We sequenced and critically examined JCPyV NCCR from isolates detected in the cerebrospinal fluid of four newly diagnosed progressive multifocal leukoencephalopathy patients: two HIV-positive and two HIV-negative multiple sclerosis patients. More complex NCCR rearrangements were observed in the two HIV-positive patients compared to the HIV-negative multiple sclerosis patients with PML.

Conclusions: The comparison of HIV-positive and HIV-negative MS patients with PML, allowed us to evidence the presence of a common pattern of JCPyV NCCR rearrangement, characterized by the deletion of the D-block, which could be one of the initial rearrangements of JCPyV NCCR needed for the development of PML.

Citing Articles

A new evaluation of the rearranged non-coding control region of JC virus in patients with colorectal cancer.

Haghi Navand A, Jalilian S, Angali K, Karimi Babaahmadi M, Talaiezadeh A, Makvandi M BMC Cancer. 2024; 24(1):1001.

PMID: 39134946 PMC: 11320957. DOI: 10.1186/s12885-024-12684-x.


Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.

Rindi L, Zace D, Braccialarghe N, Massa B, Barchi V, Iannazzo R Drug Saf. 2024; 47(4):333-354.

PMID: 38321317 DOI: 10.1007/s40264-023-01383-4.


Polyomavirus Wakes Up and Chooses Neurovirulence.

Butic A, Spencer S, Shaheen S, Lukacher A Viruses. 2023; 15(10).

PMID: 37896889 PMC: 10612099. DOI: 10.3390/v15102112.


Nationwide Laboratory Surveillance of Progressive Multifocal Leukoencephalopathy in Japan: Fiscal Years 2011-2020.

Nakamichi K, Miura Y, Shimokawa T, Takahashi K, Suzuki T, Funata N Viruses. 2023; 15(4).

PMID: 37112948 PMC: 10144269. DOI: 10.3390/v15040968.


Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk.

Zingaropoli M, Pasculli P, Tartaglia M, Dominelli F, Ciccone F, Taglietti A Biology (Basel). 2023; 12(4).

PMID: 37106787 PMC: 10135639. DOI: 10.3390/biology12040587.


References
1.
Gosert R, Kardas P, Major E, Hirsch H . Rearranged JC virus noncoding control regions found in progressive multifocal leukoencephalopathy patient samples increase virus early gene expression and replication rate. J Virol. 2010; 84(20):10448-56. PMC: 2950575. DOI: 10.1128/JVI.00614-10. View

2.
McIlroy D, Halary F, Bressollette-Bodin C . Intra-patient viral evolution in polyomavirus-related diseases. Philos Trans R Soc Lond B Biol Sci. 2019; 374(1773):20180301. PMC: 6501910. DOI: 10.1098/rstb.2018.0301. View

3.
Dynan W, Chervitz S . Characterization of a minimal simian virus 40 late promoter: enhancer elements in the 72-base-pair repeat not required. J Virol. 1989; 63(3):1420-7. PMC: 247844. DOI: 10.1128/JVI.63.3.1420-1427.1989. View

4.
Iannetta M, Zingaropoli M, Bellizzi A, Morreale M, Pontecorvo S, DAbramo A . Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation. PLoS One. 2016; 11(8):e0160277. PMC: 4972347. DOI: 10.1371/journal.pone.0160277. View

5.
Pavlovic D, Patera A, Nyberg F, Gerber M, Liu M . Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015; 8(6):255-73. PMC: 4643867. DOI: 10.1177/1756285615602832. View